This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CDP323
Description: CDP323 is an orally active small molecule a4-integrin inhibitor. CDP323 blocks the binding of vascular cell adhesion molecule 1 (VCAM-1) binding to VLA-4.
Deal Structure: October 2006: UCB and Biogen announced a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications.
Under terms of the agreement, UCB will receive upfront and additional payments for development and commercial milestones in excess of $200 million US dollars. Furthermore Biogen Idec will contribute significantly to clinical costs for Phase II and Phase III studies. All commercialization costs and profits will be shared equally.
Partners: Biogen, Inc.
CDP 323 News
Pink Sheet chart: Biogen Idec Pipeline
Additional information available to subscribers only: